Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 11/20 | 0.51 |
| ▸ | CTSB | P07858 | 9/20 | 0.51 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12115236 | 0.92 | CTSL (0.61) | CTSLCTSBCTSSCTSKMEN1 | |
| SCHEMBL12112871 | 0.88 | CTSL (0.58) | CTSLCTSBCTSSCTSKMEN1 | |
| SCHEMBL12112868 | 0.83 | MEN1 (0.60) | CTSLCTSBCTSSCTSKMEN1 | |
| SCHEMBL12115231 | 0.82 | CTSL (0.63) | CTSLCTSBCTSSCTSKMEN1 | |
| SCHEMBL4332109 | 0.82 | KDM4E (0.53) | KMT2APOLBKDM4EOPRM1OPRD1 | |
| SCHEMBL12115112 | 0.80 | CTSL (0.52) | CTSLCTSBCTSSCTSKMEN1 | |
| SCHEMBL11711766 | 0.79 | CASP1 (0.52) | CTSLCTSBCTSSCTSKMEN1 | |
| SCHEMBL1701577 | 0.77 | CTSL (0.55) | CTSLCTSBCTSSCTSKMEN1 | |
| SCHEMBL8098620 | 0.77 | CTSL (0.55) | CTSLCTSBCTSSCTSKMEN1 | |
| SCHEMBL12112892 | 0.76 | POLB (0.43) | CTSLCTSBCTSSCTSKMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275638-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
| WO-2009147221-A1 | SMALL MOLECULE LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275638-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ADIPOR2, GPR119, ADIPOR1 | CTSL 1288/4885CTSB 2395/4885CTSS 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.